Related Experiment Video
Updated: Jun 15, 2026
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
Outcomes of Patients With Interstitial Lung Disease and Early-Stage Non-Small Cell Lung Cancer Treated With
Samantha Q Vuong1, Manlu Liu1, Noah W Tsarovsky1
1Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI; University of Wisconsin School of Medicine and Public Health, Madison, WI.
Purpose:
To characterize pulmonary events after stereotactic body radiotherapy (SBRT) in patients with non-small cell lung cancer (NSCLC) and interstitial lung disease (ILD).
Materials And Methods:
Patients with Stage I-II NSCLC receiving SBRT from 2004 to 2024 were reviewed. Radiation pneumonitis (RP) and lung infection were scored. Clinical and dosimetric predictors for grade ≥2 RP and pulmonary-related hospitalizations within one year were assessed using univariate analysis and multivariable analysis (MVA), adjusted for the competing risk of death. Overall survival (OS) was evaluated using the log rank test.
Results:
Of the 500 patients included, 31 (6.2%) had ILD. Grade ≥2 RP was observed in 5 (16.1%) patients with ILD and 17 (3.6%) patients without ILD (P = .001). Grade ≥3 RP was observed in 2 (6.5%) patients with ILD and 4 (0.9%) patients without ILD (P = .048). No patient had grade 4 or higher RP. On MVA, ILD (HR: 4.44, 95% CI: 1.50-11.32, P = .009) and higher mean lung dose (HR: 1.34, 95% CI: 1.05-1.62, P = .02) predicted for RP. ILD also predicted for pulmonary-related hospitalizations (P < .05) and worse OS (P = .002). The median OS was 36.1 months (range 3.7-76.1 months) in patients with ILD and 54.3 months (range 0.8-150.3 months) in patients without ILD (P <. 001). Two patients with ILD (6.5%) had respiratory deterioration and died within 1 year.
Conclusion:
ILD is associated with increased risk of grade ≥2 RP within 1 year of SBRT and poorer OS in patients with NSCLC.
